Identification

Name
Furazolidone
Accession Number
DB00614  (APRD00988)
Type
Small Molecule
Groups
Approved, Investigational, Vet Approved
Description

A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)

Structure
Thumb
Synonyms
  • 3-(5'-Nitrofurfuralamino)-2-oxazolidone
  • 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone
  • 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone
  • 3-[(5-Nitrofurylidene)amino]-2-oxazolidone
  • 3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone
  • 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine
  • Furazolidona
  • Furazolidone
  • Furazolidonum
  • FZL
  • N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone
  • N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one
  • Nitrofurazolidone
  • Nitrofurazolidonum
External IDs
USAF EA-1
International/Other Brands
Dependal-M (GlaxoSmithKline) / Furoxone (Roberts Laboratories)
Categories
UNII
5J9CPU3RE0
CAS number
67-45-8
Weight
Average: 225.1583
Monoisotopic: 225.038570349
Chemical Formula
C8H7N3O5
InChI Key
PLHJDBGFXBMTGZ-WEVVVXLNSA-N
InChI
InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+
IUPAC Name
3-{[(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one
SMILES
[O-][N+](=O)C1=CC=C(O1)C=NN1CCOC1=O

Pharmacology

Indication

For the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.

Structured Indications
Not Available
Pharmacodynamics

Furoxone has a broad antibacterial spectrum covering the majority of gastrointestinal tract pathogens including E. coli, staphylococci, Salmonella, Shigella, Proteus, Aerobacter aerogenes, Vibrio cholerae and Giardia lamblia. Its bactericidal activity is based upon its interference with DNA replication and protein production; this antimicrobial action minimizes the development of resistant organisms.

Mechanism of action

Furazolidone and its related free radical products are believed to bind DNA and induce cross-links. Bacterial DNA is particularly susceptible to this drug leading to high levels of mutations (transitions and transversions) in the bacterial chromosome.

TargetActionsOrganism
ADNA
cross-linking/alkylation
Human
Absorption

Radiolabeled drug studies indicate that furazolidone is well absorbed following oral administration

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Furazolidone is rapidly and extensively metabolized; the primary metabolic pathway identified begins with nitro-reduction to the aminofuran derivative. Two major metabolites are produced: 3-amino-2-oxazolidone (AOZ) or beta-hydroxyethylhydrazine (HEH). AOZ is responsible for monoamine oxidase inhibition. Detoxification and elimination of the drug is done primarily by conjugation with glutathione.

Route of elimination
Not Available
Half life

10 minutes

Clearance
Not Available
Toxicity

Reactions to Furoxone have been reported including a fall in blood pressure, urticaria, fever, arthralgia, and a vesicular morbilliform rash. Other adverse effects can include a brown discoloration of the urine; hemolysis can occur in G6PDH-deficient patients. The drug has a monoamine oxidase (MAO) inhibitory effect and should never be given concurrently to individuals already taking MAO inhibitors.

Affected organisms
  • Microbes (bacteria, parasites)
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineFurazolidone may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineFurazolidone may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineFurazolidone may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineFurazolidone may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcarboseFurazolidone may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololFurazolidone may increase the hypotensive activities of Acebutolol.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Furazolidone.Experimental
AlbiglutideFurazolidone may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Furazolidone.Approved, Illicit
AliskirenFurazolidone may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Furazolidone.Approved, Investigational
AlogliptinFurazolidone may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Furazolidone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Furazolidone.Illicit
AlprenololFurazolidone may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Furazolidone.Approved
AmbrisentanFurazolidone may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineFurazolidone may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineFurazolidone may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineFurazolidone may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Amoxapine.Approved
AmphetamineFurazolidone may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Furazolidone.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Arformoterol.Approved, Investigational
AtenololFurazolidone may increase the hypotensive activities of Atenolol.Approved
AtomoxetineFurazolidone may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineFurazolidone may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Bambuterol.Approved, Investigational
BenazeprilFurazolidone may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideFurazolidone may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinFurazolidone may increase the hypertensive activities of Benmoxin.Withdrawn
BenzphetamineFurazolidone may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilFurazolidone may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Furazolidone.Approved
BetaxololFurazolidone may increase the hypotensive activities of Betaxolol.Approved
BethanidineFurazolidone may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Furazolidone is combined with Bezafibrate.Approved
BietaserpineFurazolidone may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostFurazolidone may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololFurazolidone may increase the hypotensive activities of Bisoprolol.Approved
BosentanFurazolidone may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Furazolidone may increase the hypotensive activities of BQ-123.Investigational
BretyliumFurazolidone may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Brimonidine.Approved
BrofaromineFurazolidone may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineFurazolidone may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BupranololFurazolidone may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Furazolidone.Approved, Illicit, Investigational, Vet Approved
BupropionFurazolidone may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Furazolidone.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Furazolidone.Approved, Illicit, Vet Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Furazolidone.Approved
CadralazineFurazolidone may increase the hypotensive activities of Cadralazine.Experimental
CafedrineFurazolidone may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinFurazolidone may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanFurazolidone may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilFurazolidone may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilFurazolidone may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilFurazolidone may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Furazolidone.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Furazolidone.Illicit, Investigational, Vet Approved
CaroxazoneFurazolidone may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololFurazolidone may increase the hypotensive activities of Carteolol.Approved
CarvedilolFurazolidone may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololFurazolidone may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideFurazolidone may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineFurazolidone may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamideFurazolidone may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneFurazolidone may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineFurazolidone may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilFurazolidone may increase the hypotensive activities of Cilazapril.Approved
CirazolineFurazolidone may increase the hypertensive activities of Cirazoline.Experimental
CitalopramFurazolidone may increase the serotonergic activities of Citalopram.Approved
ClemastineFurazolidone may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineFurazolidone may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidineFurazolidone may increase the hypotensive activities of Clonidine.Approved
CloranololFurazolidone may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Furazolidone.Approved, Illicit
CryptenamineFurazolidone may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Furazolidone.Approved
CyclopenthiazideFurazolidone may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideFurazolidone may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineFurazolidone may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinFurazolidone may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineFurazolidone may increase the serotonergic activities of Dapoxetine.Investigational
DebrisoquinFurazolidone may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilFurazolidone may increase the hypotensive activities of Delapril.Experimental
DeserpidineFurazolidone may increase the hypotensive activities of Deserpidine.Approved
DesipramineFurazolidone may increase the serotonergic activities of Desipramine.Approved
DesvenlafaxineFurazolidone may increase the serotonergic activities of Desvenlafaxine.Approved
DexmethylphenidateFurazolidone may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineFurazolidone may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanFurazolidone may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Furazolidone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Furazolidone.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Furazolidone.Approved, Investigational
DiazoxideFurazolidone may increase the hypotensive activities of Diazoxide.Approved
DibenzepinFurazolidone may increase the serotonergic activities of Dibenzepin.Experimental
diethylnorspermineFurazolidone may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionFurazolidone may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineFurazolidone may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Furazolidone.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Furazolidone.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Furazolidone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Furazolidone.Experimental, Illicit
DiltiazemFurazolidone may increase the hypotensive activities of Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Furazolidone.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Furazolidone is combined with Dipivefrin.Approved
DisopyramideFurazolidone may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideFurazolidone may increase the hypotensive activities of Dorzolamide.Approved
DosulepinFurazolidone may increase the serotonergic activities of Dosulepin.Approved
DoxapramFurazolidone may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinFurazolidone may increase the hypotensive activities of Doxazosin.Approved
DoxepinFurazolidone may increase the serotonergic activities of Doxepin.Approved
DoxylamineFurazolidone may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Furazolidone.Experimental
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Furazolidone.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Furazolidone is combined with Droxidopa.Approved, Investigational
DulaglutideFurazolidone may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineFurazolidone may increase the serotonergic activities of Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Furazolidone.Experimental, Illicit
EfonidipineFurazolidone may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Furazolidone.Approved, Investigational
EmpagliflozinFurazolidone may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilFurazolidone may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatFurazolidone may increase the hypotensive activities of Enalaprilat.Approved
EndralazineFurazolidone may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Furazolidone.Approved, Investigational
EpanololFurazolidone may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Furazolidone is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineFurazolidone may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolFurazolidone may increase the hypotensive activities of Epoprostenol.Approved
EprosartanFurazolidone may increase the hypotensive activities of Eprosartan.Approved
ErgotamineFurazolidone may increase the hypertensive activities of Ergotamine.Approved
EscitalopramFurazolidone may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapineFurazolidone may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Furazolidone.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Furazolidone.Approved, Illicit
EtoperidoneFurazolidone may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Furazolidone.Illicit, Vet Approved
ExenatideFurazolidone may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineFurazolidone may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamFurazolidone may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Fenoterol.Approved, Investigational
FentanylFentanyl may increase the serotonergic activities of Furazolidone.Approved, Illicit, Investigational, Vet Approved
Ferulic acidFurazolidone may increase the hypotensive activities of Ferulic acid.Experimental
FluoxetineFurazolidone may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluvoxamineFurazolidone may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Formoterol.Approved, Investigational
FosinoprilFurazolidone may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Furazolidone.Approved, Investigational
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Furazolidone.Experimental
GliclazideFurazolidone may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideFurazolidone may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideFurazolidone may increase the hypoglycemic activities of Glipizide.Approved
GlyburideFurazolidone may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzFurazolidone may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelFurazolidone may increase the hypotensive activities of Guanadrel.Approved
GuanazodineFurazolidone may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineFurazolidone may increase the hypotensive activities of Guanethidine.Approved
GuanfacineFurazolidone may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorFurazolidone may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzFurazolidone may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanFurazolidone may increase the hypotensive activities of Guanoxan.Experimental
HarmalineFurazolidone may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Furazolidone.Approved, Illicit, Investigational
HexamethoniumFurazolidone may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineFurazolidone may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazineFurazolidone may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideFurazolidone may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideFurazolidone may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineFurazolidone may increase the hypertensive activities of Hydroxyamphetamine.Approved
ImidaprilFurazolidone may increase the hypotensive activities of Imidapril.Investigational
ImipramineFurazolidone may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Indacaterol.Approved
IndalpineFurazolidone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideFurazolidone may increase the hypotensive activities of Indapamide.Approved
IndenololFurazolidone may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminFurazolidone may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartFurazolidone may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirFurazolidone may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineFurazolidone may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineFurazolidone may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanFurazolidone may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproFurazolidone may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Furazolidone.Approved
IprindoleFurazolidone may increase the serotonergic activities of Iprindole.Experimental
IproclozideFurazolidone may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Furazolidone.Withdrawn
IrbesartanFurazolidone may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Furazolidone.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Isoprenaline.Approved
IsradipineFurazolidone may increase the hypotensive activities of Isradipine.Approved
KetanserinFurazolidone may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Furazolidone.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Furazolidone.Approved, Nutraceutical, Withdrawn
LabetalolFurazolidone may increase the hypotensive activities of Labetalol.Approved
LacidipineFurazolidone may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostFurazolidone may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineFurazolidone may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Furazolidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Furazolidone.Approved, Investigational
LevomilnacipranFurazolidone may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinFurazolidone may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Furazolidone.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Levosalbutamol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Furazolidone is combined with Linezolid.Approved, Investigational
LinsidomineFurazolidone may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideFurazolidone may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineFurazolidone may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilFurazolidone may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Furazolidone.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Furazolidone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Furazolidone.Illicit
LofepramineFurazolidone may increase the serotonergic activities of Lofepramine.Experimental
LofexidineFurazolidone may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanFurazolidone may increase the hypotensive activities of Losartan.Approved
MacitentanFurazolidone may increase the hypotensive activities of Macitentan.Approved
ManidipineFurazolidone may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Furazolidone.Approved
MebanazineFurazolidone may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineFurazolidone may increase the hypotensive activities of Mecamylamine.Approved
MecaserminFurazolidone may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MephedroneFurazolidone may increase the hypertensive activities of Mephedrone.Investigational
MephentermineFurazolidone may increase the hypertensive activities of Mephentermine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Furazolidone.Experimental
MequitazineFurazolidone may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolFurazolidone may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminFurazolidone may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Furazolidone.Approved, Illicit
MethamphetamineFurazolidone may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoserpidineFurazolidone may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineFurazolidone may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Furazolidone.Experimental
MethyldopaThe risk or severity of adverse effects can be increased when Furazolidone is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Furazolidone.Experimental
Methylene blueFurazolidone may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateFurazolidone may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetipranololFurazolidone may increase the hypotensive activities of Metipranolol.Approved
MetolazoneFurazolidone may increase the hypotensive activities of Metolazone.Approved
MetoprololFurazolidone may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineFurazolidone may increase the hypotensive activities of Metyrosine.Approved
MianserinFurazolidone may increase the neurotoxic activities of Mianserin.Approved, Investigational
MibefradilFurazolidone may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineFurazolidone may increase the hypertensive activities of Midodrine.Approved
MidomafetamineFurazolidone may increase the hypertensive activities of Midomafetamine.Experimental, Illicit, Investigational
MifepristoneFurazolidone may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolFurazolidone may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranFurazolidone may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Furazolidone.Approved
MinoxidilFurazolidone may increase the hypotensive activities of Minoxidil.Approved
MirtazapineFurazolidone may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAFurazolidone may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Furazolidone is combined with Moclobemide.Approved
MoexiprilFurazolidone may increase the hypotensive activities of Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Morphine.Approved, Investigational
MoxonidineFurazolidone may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineFurazolidone may increase the hypotensive activities of Muzolimine.Experimental
NadololFurazolidone may increase the hypotensive activities of Nadolol.Approved
NaftopidilFurazolidone may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Furazolidone.Approved
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Furazolidone.Approved, Investigational
NateglinideFurazolidone may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololFurazolidone may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneFurazolidone may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Furazolidone.Withdrawn
NicardipineFurazolidone may increase the hypotensive activities of Nicardipine.Approved
NicorandilFurazolidone may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineFurazolidone may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineFurazolidone may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineFurazolidone may increase the hypotensive activities of Nimodipine.Approved
NisoldipineFurazolidone may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineFurazolidone may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideFurazolidone may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineFurazolidone may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Furazolidone.Approved, Illicit
NortriptylineFurazolidone may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinFurazolidone may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Olanzapine.Approved, Investigational
OlmesartanFurazolidone may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Olodaterol.Approved
OmapatrilatFurazolidone may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolFurazolidone may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Furazolidone.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Orciprenaline.Approved
OxprenololFurazolidone may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Furazolidone.Approved, Investigational, Vet Approved
PargylineFurazolidone may increase the hypotensive activities of Pargyline.Approved
ParoxetineFurazolidone may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololFurazolidone may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineFurazolidone may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Furazolidone.Approved, Vet Approved
PentoliniumFurazolidone may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Furazolidone.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilFurazolidone may increase the hypotensive activities of Perindopril.Approved
PethidineFurazolidone may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Furazolidone.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Furazolidone.Approved
PheniprazineFurazolidone may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Furazolidone.Experimental
PhenoxybenzamineFurazolidone may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineFurazolidone may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineFurazolidone may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineFurazolidone may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineFurazolidone may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Furazolidone.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Furazolidone.Investigational
PinacidilFurazolidone may increase the hypotensive activities of Pinacidil.Withdrawn
PindololFurazolidone may increase the hypotensive activities of Pindolol.Approved
PioglitazoneFurazolidone may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Furazolidone.Investigational
PirlindolePirlindole may increase the hypertensive activities of Furazolidone.Approved
PivhydrazineFurazolidone may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenFurazolidone may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorFurazolidone may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideFurazolidone may increase the hypotensive activities of Polythiazide.Approved
PramlintideFurazolidone may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinFurazolidone may increase the hypotensive activities of Prazosin.Approved
ProcarbazineFurazolidone may increase the hypertensive activities of Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Procaterol.Approved, Investigational
PropranololFurazolidone may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineFurazolidone may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Furazolidone.Investigational
PseudoephedrineFurazolidone may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilFurazolidone may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineFurazolidone may increase the hypoglycemic activities of Quinine.Approved
RamiprilFurazolidone may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Furazolidone.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Furazolidone.Approved
RemikirenFurazolidone may increase the hypotensive activities of Remikiren.Approved
RepaglinideFurazolidone may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineFurazolidone may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Reserpine.Approved, Investigational
RilmenidineFurazolidone may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatFurazolidone may increase the hypotensive activities of Riociguat.Approved
RitobegronFurazolidone may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Ritodrine.Approved, Investigational
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Furazolidone.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Furazolidone.Approved, Investigational
RosiglitazoneFurazolidone may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineFurazolidone may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Salmeterol.Approved
SaprisartanFurazolidone may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinFurazolidone may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
SelexipagFurazolidone may increase the hypotensive activities of Selexipag.Approved
SertralineFurazolidone may increase the serotonergic activities of Sertraline.Approved
SitagliptinFurazolidone may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanFurazolidone may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilFurazolidone may increase the hypotensive activities of Spirapril.Approved
SufentanilSufentanil may increase the serotonergic activities of Furazolidone.Approved, Investigational
SulfadiazineFurazolidone may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleFurazolidone may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleFurazolidone may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Furazolidone.Approved, Investigational
SunitinibFurazolidone may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololFurazolidone may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Furazolidone.Approved
TelmisartanFurazolidone may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilFurazolidone may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Terbutaline.Approved
TerlipressinFurazolidone may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Furazolidone.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Furazolidone.Approved
TetrahydropalmatineFurazolidone may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineFurazolidone may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineFurazolidone may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Furazolidone.Approved, Investigational
TiboloneFurazolidone may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenFurazolidone may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Furazolidone.Experimental
TimololFurazolidone may increase the hypotensive activities of Timolol.Approved
TolazamideFurazolidone may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineFurazolidone may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideFurazolidone may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Furazolidone.Approved, Withdrawn
TolonidineFurazolidone may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Furazolidone.Approved
TorasemideFurazolidone may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Furazolidone.Approved, Investigational
TrandolaprilFurazolidone may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineFurazolidone may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Furazolidone.Approved
TravoprostFurazolidone may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Trazodone.Approved, Investigational
TreprostinilFurazolidone may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideFurazolidone may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinFurazolidone may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanFurazolidone may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineFurazolidone may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneFurazolidone may increase the hypotensive activities of Unoprostone.Approved
UrapidilFurazolidone may increase the hypotensive activities of Urapidil.Investigational
ValsartanFurazolidone may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineFurazolidone may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Furazolidone.Approved
VincamineFurazolidone may increase the hypotensive activities of Vincamine.Experimental
VinpocetineFurazolidone may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Furazolidone.Approved
XipamideFurazolidone may increase the hypotensive activities of Xipamide.Experimental
XylometazolineFurazolidone may increase the hypotensive activities of Xylometazoline.Approved
ZimelidineFurazolidone may increase the serotonergic activities of Zimelidine.Withdrawn
ZofenoprilFurazolidone may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Furazolidone.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Drake, G.D., Gever, G. and Hayes, K.J.; U.S. Patent 2,759,931; August 21, 1956; assigned to The Norwich Pharmacal Company. Gever, G. and O'Keefe, C.J.; U.S. Patent 2,927,l IO; March 1, 1960; assigned to The Norwich Pharmacal Company.

US2742462
General References
Not Available
External Links
Human Metabolome Database
HMDB14752
KEGG Drug
D00830
KEGG Compound
C07999
PubChem Compound
3435
PubChem Substance
46507291
ChemSpider
4481255
ChEBI
5195
ChEMBL
CHEMBL1103
Therapeutic Targets Database
DAP000993
PharmGKB
PA164746760
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Furazolidone
ATC Codes
G01AX06 — Furazolidone
MSDS
Download (74.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentFunctional Dyspepsia / Scarred Peptic Ulcer1
4Not Yet RecruitingTreatmentAntimicrobial Susceptibility Testing / Triple Therapy1
4RecruitingTreatmentAntimicrobial Susceptibility Testing / Bacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
Not AvailableCompletedTreatmentTreatment of Helicobacter Pylori1

Pharmacoeconomics

Manufacturers
  • Shire development inc
Packagers
  • Professional Co.
Dosage forms
Not Available
Prices
Unit descriptionCostUnit
Furazolidone powder2.04USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)254-256Drake, G.D., Gever, G. and Hayes, K.J.; U.S. Patent 2,759,931; August 21, 1956; assigned to The Norwich Pharmacal Company. Gever, G. and O'Keefe, C.J.; U.S. Patent 2,927,l IO; March 1, 1960; assigned to The Norwich Pharmacal Company
water solubility40 mg/L (at 25 °C)MERCK INDEX (1996); pH 6
logP-0.04DEBNATH,AK ET AL. (1991)
Predicted Properties
PropertyValueSource
Water Solubility0.364 mg/mLALOGPS
logP0.15ALOGPS
logP0.87ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)-2.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area100.86 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity51.09 m3·mol-1ChemAxon
Polarizability19.74 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9038
Blood Brain Barrier+0.9117
Caco-2 permeable-0.5736
P-glycoprotein substrateNon-substrate0.7829
P-glycoprotein inhibitor INon-inhibitor0.7761
P-glycoprotein inhibitor IINon-inhibitor0.9597
Renal organic cation transporterNon-inhibitor0.8351
CYP450 2C9 substrateNon-substrate0.8117
CYP450 2D6 substrateNon-substrate0.8415
CYP450 3A4 substrateSubstrate0.5984
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9134
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.928
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8828
Ames testAMES toxic0.9108
CarcinogenicityNon-carcinogens0.9097
BiodegradationReady biodegradable0.8978
Rat acute toxicity2.1639 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7889
hERG inhibition (predictor II)Non-inhibitor0.9057
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as nitrofurans. These are compounds containing a furan ring which bears a nitro group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Furans
Sub Class
Nitrofurans
Direct Parent
Nitrofurans
Alternative Parents
Nitroaromatic compounds / Oxazolidinones / Heteroaromatic compounds / Organic carbonic acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Organic oxoazanium compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 3 more
Substituents
Nitroaromatic compound / 2-nitrofuran / Oxazolidinone / Oxazolidine / Heteroaromatic compound / C-nitro compound / Carbonic acid derivative / Organic nitro compound / Organic oxoazanium / Allyl-type 1,3-dipolar organic compound
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
oxazolidines, nitrofuran antibiotic (CHEBI:5195)

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
Yes
Actions
Cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Meng J, Mangat SS, Grudzinski IP, Law FC: Evidence of 14C-furazolidone metabolite binding to the hepatic DNA of trout. Drug Metabol Drug Interact. 1998;14(4):209-19. [PubMed:10694929]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [PubMed:12623758]
  2. Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [PubMed:10543364]
  3. Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [PubMed:2032659]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [PubMed:12623758]
  2. Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [PubMed:10543364]
  3. Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [PubMed:2032659]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:40